Tiburio is dedicated to advancing novel treatments for serious neuroendocrine disorders such as non-functioning pituitary adenoma (NFPA). In these diseases, the development of distinct non-metastatic tumors in the pituitary gland can result in life-altering and potentially life-threatening consequences for patients. Tiburio is currently developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma (NFPA). Tiburio’s development stage pipeline includes TBR-065, a novel therapy for other rare neuroendocrine diseases. The company was launched out of orphan drug accelerator Cydan, with financing from life science investors NEA, Lundbeckfonden Ventures, Longitude Capital and Alexandria Venture Investments.